Clinically significant interstitial lung disease in limited scleroderma: Histopathology, clinical features, and survival

Chest

Volumn 134, Issue 3, 2008, Pages 601-605

  Fischer, Aryeh ^a   Swigris, Jeffrey J ^a   Groshong, Steve D ^a   Cool, Carlyne D ^a   Sahin, Hakan ^a   Lynch, David A ^a   Curran Everett, Douglas ^a   Gillis, JoAnn Z ^a   Meehan, Richard T ^a   Brown, Kevin K ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Histopathology; Interstitial lung disease; Scleroderma; Survival; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; SCL 70 ANTIBODY;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; FEMALE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOG RANK TEST; LOW DRUG DOSE; LUNG BIOPSY; LUNG CAPACITY; LUNG DIFFUSION; LUNG FIBROSIS; MALE; MEDICAL RECORD REVIEW; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCLERODERMA; SKIN DISEASE; SURVIVAL RATE; SYMPTOMATOLOGY;

EID: 51649098464     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0053     Document Type: Article

References (14)

1. Steen VD. Epidemiology of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. Barcelona, Spain: Elsevier Doyma, 2003; 1455-1462
2. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003; 29:371-390
3. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277-304
4. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586
5. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:121-127
6. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-711
7. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma): subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-590
8. Lynch DA, Travis WD, Muller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236:10-21
9. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666
10. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970
11. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997; 24:81-85
12. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283-1289
13. Lomeo RM, Cornella RJ, Schabel SI, et al. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87:525-527
14. Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130:976-981